Cargando…

Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer

Recently, a tumor-autonomous cytochrome P450 (CYP)-3A5-mediated resistance to cancer therapy has been demonstrated in pancreatic ductal adenocarcinoma. Expression of CYP3A5, which is involved in the degradation of irinotecan, has also been reported in colorectal cancer (CRC). The aim of the present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buck, Emanuel, Sprick, Martin, Gaida, Matthias M., Grüllich, Carsten, Weber, Tim Frederik, Herpel, Esther, Bruckner, Thomas, Koschny, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403523/ https://www.ncbi.nlm.nih.gov/pubmed/30881507 http://dx.doi.org/10.3892/ol.2019.10043

Ejemplares similares

Aspiration risk in relation to Glasgow Coma Scale score and clinical parameters in patients with severe acute alcohol intoxication: a single-centre, retrospective study
por: Conzelmann, Michael, et al.
Publicado: (2021)

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
por: Glimelius, B, et al.
Publicado: (2011)

Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population‐based study
por: Alwers, Elizabeth, et al.
Publicado: (2020)

Enormously dilated pancreatic duct
por: Koschny, Ronald, et al.
Publicado: (2022)

Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma — Prognostic and Translational Implications()
por: Zhou, Xiaoguang, et al.
Publicado: (2015)

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer
por: Veronese, M L, et al.
Publicado: (2005)

Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore C™) and 5-Fluorouracil
por: Hare, Jennifer I., et al.
Publicado: (2013)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2003)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Alliot, C, et al.
Publicado: (2004)

Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
por: Huang, Jiao-Ren, et al.
Publicado: (2019)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis()()
por: Erdem, Zeynep N., et al.
Publicado: (2017)

Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
por: Scarabel, Lucia, et al.
Publicado: (2020)

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
por: Davis, S. Lindsey, et al.
Publicado: (2022)

Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells
por: Frerker, Bernd, et al.
Publicado: (2023)

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2017)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
por: Quackenbush, Kevin S., et al.
Publicado: (2016)

Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
por: Yue, Bei, et al.
Publicado: (2021)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2016)

Reply: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2004)

Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer
por: Okunaka, Mashiro, et al.
Publicado: (2021)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

Irinotecan/scFv co-loaded liposomes coaction on tumor cells and CAFs for enhanced colorectal cancer therapy
por: Li, Zhaohuan, et al.
Publicado: (2021)

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer
por: Blazevic, Ilfad, et al.
Publicado: (2020)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review
por: Ozawa, Shogo, et al.
Publicado: (2021)

Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial
por: Berger, Anne Katrin, et al.
Publicado: (2018)

Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts
por: Tamura, Kenji, et al.
Publicado: (1997)

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
por: Bathe, Oliver F, et al.
Publicado: (2009)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
por: Allegrini, G, et al.
Publicado: (2008)

Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Alliot, C
Publicado: (2006)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004)

Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan
por: Choi, Seung Ho, et al.
Publicado: (2015)

Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer
por: Makondi, Precious Takondwa, et al.
Publicado: (2017)

Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
por: Sharma, Anup, et al.
Publicado: (2017)

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
por: Vitiello, Pietro Paolo, et al.
Publicado: (2021)

Integrated Bioinformatics Analysis of the Hub Genes Involved in Irinotecan Resistance in Colorectal Cancer
por: Kryczka, Jakub, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o160h4icfhu97vroh1n9c4fbha